Strategos: CORRECTION -- Strateos combines Transcriptic and 3Scan to become Premier Drug Discovery Technology Partner for the Pharmaceutical Industry

SAN FRANCISCO, June 03, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Strateos, please note that the link in the About paragraph, should lead to http://strateos.com/.The boards of Transcriptic and 3Scan have unanimously approved an agreement to merge companies to combine their considerable engineering capabilities in developing automated systems for chemistry, biology, and tissue analysis. The resulting new company is Strateos .Transcriptic developed the first robotic cloud laboratory platform for on-demand life science research, which is currently in use at several top pharmaceutical and biotechnology companies. 3Scan combines automation, machine learning and computer vision to extract spatial data from tissue samples and create detailed 3D representations as well as quantitative analysis of complex anatomical structures. Now these two portfolios will be combined to offer a suite of technologies for accelerating drug discovery and early development.Both companies have track records integrating novel artificial intelligence and robotics technologies into the pharmaceutical drug discovery process, and each has realized revenue in-line with the value created by their novel products and services. Integration of the two companies will be aided by their proximity, with development and production teams operating across California.In support of the Strateos mission, DCVC (Data ...